undamentalytics Newsletter

Edgewise Therapeutics, Inc. valuation and forecast

Explore the models for Edgewise Therapeutics, Inc., adjust their assumptions and compare your own valuation with the platform's.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Edgewise Therapeutics, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: limited reported history: available models are shown without a Buy/Hold/Sell rating. We'll show the comparison once resolved.

Analyst recommendations

14 analysts, Oct 2026
Buy1286%
Hold214%
Sell00%

Monthly trend

  1. Oct 202639214
  2. Sep 202638213
  3. Aug 202638213
  4. Jul 202638213

Counts of recommendations published by analysts covering Edgewise Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Price history

Loading chart…

Third-party market data · may be delayed

EWTX valuation questions

How does Fundamentalytics value Edgewise Therapeutics, Inc.?
We use the models that fit Edgewise Therapeutics, Inc.'s business and available financial data. Each model has its own assumptions and data requirements. The calculator explains which models are available and lets you adjust their inputs.

Data: SEC EDGAR filings, retrieved Invalid Date. Method: how we value companies. Disclosures: research and recommendations disclosure. Back to Edgewise Therapeutics, Inc.